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Abstract: Individuals with metabolic syndrome have significantly higher risk of cardiovascular 
disease and type 2 diabetes leading to premature death mortality. Metabolic syndrome has a 
complex etiology; thus, it may require a combined and multi-targeted aerobic exercise regi-
men to improve risk factors associated with it. Therefore, the aim of this study was to evaluate 
the effect of combined continuous and interval aerobic training on patients with metabolic 
syndrome. Thirty adult male with metabolic syndrome (54±8 years) were randomly divided 
into two groups: test training group (TTG; n=15) and control group (CG; n=15). Subjects in 
TTG performed combined continuous and interval aerobic training using a motorized treadmill 
three times per week for 16 weeks. Subjects in CG were advised to continue with their normal 
activities of life. Twenty-two men completed the study (eleven men in each group). At the end 
of the study, in TTG, there were significant (for all, P,0.05) reductions in total body weight 
(-3.2%), waist circumference (-3.43 cm), blood pressure (up to -12.7 mmHg), and plasma 
insulin, glucose, and triacylglyceride levels. Moreover, there were significant (for all, P,0.05) 
increases VO
2
max (-15.3%) and isometric strength of thigh muscle (28.1%) and high-density 
lipoprotein in TTG. None of the above indices were changed in CG at the end of 16-week study 
period. Our study suggests that adoption of a 16-week combined continuous and interval aerobic 
training regimen in men with metabolic syndrome could significantly reduce cardiovascular 
risk factors in these patients.
Keywords: metabolic syndrome, combined continuous and interval training, blood pressure, 
insulin sensitivity
Introduction
Metabolic syndrome is a collection of interrelated cardiovascular risk factors includ-
ing abdominal obesity, hypertension, glucose intolerance, insulin resistance, and 
dyslipidemia.1,2 The prevalence of metabolic syndrome appears to be influenced by 
genetic make-up, being high among Asians compared with white Caucasians for a given 
total body weight.3,4 Individuals with the metabolic syndrome have significantly higher 
risk of heart disease (two- to threefold), stroke (twofold), and diabetes (fivefold).5–7
Improvement of body composition status, physical performance, cardiovascular 
factors, and metabolic risk factors is the priority of treatment programs for patients 
with metabolic syndrome.8–10 Development of central or visceral fat is consistent with 
higher risk of metabolic syndrome, while small amounts of weight loss, especially 
visceral fat, potentially prevent or reverse metabolic syndrome and its deleterious 
outcomes.11,12 Moreover, a low aerobic exercise capacity appears to be the strongest 
predictor of metabolic syndrome.13 Indeed, each 1 mL/kg/min increment  improvement 
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in VO
2
max was associated with 7% lower risk of metabolic 
syndrome.14 Furthermore, the muscular strength is gener-
ally considered as a function of physical fitness and health. 
The muscular strength is inversely associated with the 
prevalence of the metabolic syndrome independently of the 
aerobic fitness.15 Improvements in other key components 
of the metabolic syndrome, namely hypertension, glucose 
intolerance, abnormal lipid profile, and insulin resistance, 
are mainstay of the non-pharmacological treatment of the 
metabolic syndrome.16–18 The lifestyle (behavioral) modifica-
tion (weight control, diet, exercise, smoking cessation) and 
aerobic exercise training have been shown to be effective 
interventions for the prevention and treatment of the meta-
bolic syndrome,19 although with a varying degree of success. 
Therefore, considering the complex etiology of the metabolic 
syndrome, we have hypothesized that combination of a multi-
targeted aerobic training would be an optimal approach to 
tackle all the risk factors simultaneously in patients with 
metabolic syndrome.
Methods
subject inclusion
The study included thirty adult male (54±8 years) subjects 
with metabolic syndrome according to the definition of the 
National Cholesterol Education Program Adult Treatment 
Panel.20 The subjects had three or more of the following 
criteria: 1) waist circumference .102 cm, 2) triglycer-
ides $150 mg/dL, 3) blood pressure (BP) $130.85 mmHg, 
4) high-density lipoprotein (HDL) ,40 mg/dL, and 5) fast-
ing glucose $110 mg/dL. The baseline characteristics of the 
participants are outlined in Table 1. The inclusion criteria 
included the ability to undergo training program outlined in 
the study at Imam Reza University Hospital, Tabriz, Iran. All 
subjects were informed of the nature, purpose, and potential 
risks of the study, after which written informed consents were 
obtained from all participants. All subjects with a history of 
any form of cardiovascular events (myocardial infarction, tran-
sient ischemic attacks, peripheral vascular disease, heart fail-
ure, unstable angina, or stroke) were excluded from the study. 
The study was reviewed and approved by the Institutional 
Review Board on Human Experiments, Tabriz University of 
Medicine. Patients were randomized and stratified (by age and 
body mass index [BMI]) into test training group (TTG; n=15) 
and a control group (CG; n=15). A total of 22 men completed 
the study (eleven subjects from each group).
exercise protocol
Subjects in TTG performed combined continuous and 
interval aerobic training as walking and running “uphill” on 
treadmill three times per week for 16 weeks. Each session 
consisted of the following:
1. Warm-up for 5 minutes at 50% of maximum heart rate 
(MHR)
2. Twenty minutes continuous at 70% of MHR
3. Twelve (4×3)-minute intervals at 90% of MHR with 
a 3-minute active recovery at 70% of MHR between 
intervals
4. Five-minute cool-down period at 50% of MHR, giving a 
total exercise time of 54 minutes.
The subjects in CG continued with their normal daily liv-
ing activities during the 16 weeks of the study period without 
any additionally prescribed physical activities.
All subjects were also requested to continue with their 
normal diet and physical activity patterns outside of the study 
protocol. Dietary patterns were registered using a “Food Fre-
quency Questionnaire” that has been validated by the Centre 
for Endocrinology and Metabolism Research of Shahid 
Beheshti University of Medical Sciences, Tehran, Iran.21
Data acquisition
At the start of the study (day 1) and at the end of the weeks 8 
and 16, the following measurements were obtained from all 
participants.
anthropometric measurements
The subjects’ heights were measured to the nearest 0.1 cm 
using a wall-mounted Stadiometer (Yagami, Miekosha, 
Japan), and the body weights were measured to the nearest 
0.1 kg using a digital scale (Seca, Germany) with the subjects 
having only their underwear and being barefooted. BMI 
was calculated as weight in kilograms divided by the square 
of the height in meters (kg/m2). The waist circumference 
Table 1 Baseline characteristics of subjects enrolled in this study
Parameters Control  
group
Training 
test group
Physiological (mean ± sD)
 age (years) 52.8±9.5 54.5±7.8
 Weight (kg) 97.1±13.1 99.3±14.8
 Waist (cm) 110.0±6.5 112.5±9.4
 Body mass index (kg/m2) 33.8±3.7 34.7±3.6
Subjects with diagnosed diabetes
Medications (n)
 Glibenclamide 3 3
 Metformin 3 2
 statins 2 2
 angiotensin II blockers 2 1
 β-Blockers 3 1
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measurements were taken in triplicate to the nearest 0.1 cm 
using a nonelastic measuring tape on the skin midway 
between the iliac crest and the lowest rib in standing position. 
The percentage body fat was measured using Skinfold Caliper 
(Yagami) and equations set forth by the American College 
of Sports Medicine (ACSM),22 for three separate sites: chest 
pectoral, supra-iliac, and abdominal areas.22
% body fat =  (0.39287 × sum of three skinfolds)  
- (0.00105 × [sum of three skinfolds]2)  
+ (0.15772 × age) - 5.18845 (1)
Blood pressure
BP was assessed in duplicate using a manual sphygmoma-
nometer (Riester-1002; Rudolf Reister GmbH, Junginen, 
Germany) after participants sat quietly for 15 minutes, and 
the mean of the two measurements was used for statistical 
analysis.
Blood analyses
The blood samples were collected from all participants after 
at least 14 hours of fasting and abstinence from smoking. 
Furthermore, the participants were asked to abstain from 
vigorous exercise outside of the study protocol for at least 
3 days prior to blood sampling. The serum of blood samples 
was separated immediately by centrifugation at 3,000 rpm 
for 10 minutes at 4°C for measurements of insulin, glucose, 
triacylglycerides, and HDL-cholesterol concentrations. 
The insulin levels were measured by a radioimmunoassay 
(using Kit IM3210, Immunotech Company), while glucose 
concentrations were determined using an automated glucose 
analyzer (Yellow Springs Instruments (YSI), 2300 STAT). 
The plasma concentrations of triacylglycerides and HDL 
were determined by standard enzymatic methods (Roche 
Diagnostics) on a Hitachi automated spectrophotometer. 
To estimate overall insulin resistance and insulin sensitiv-
ity, the homeostasis assessment model of insulin resistance 
(HOMA-IR)23 and quantitative insulin sensitivity check index 
(QUICKI)24 methods were used, respectively.
HOMA-IR =  [fasting insulin (µU/mL)  
× fasting glucose (mmol)]/22.5 (2)
QUICKI =  1/[log fasting insulin (µU/mL)  
+ log fasting glucose (mg/dL)] (3)
cardiopulmonary function test
The cardio-respiratory fitness level was measured during a 
maximal exercise test on a treadmill (Technogym, Casena, Italy) 
according to a modified Bruce protocol after a 15-minute 
warm-up. The BP, heart rate (HR), and the Borg scale of rat-
ing of perceived exertion (RPE) were measured at 2 minutes 
of each stage of the exercise. The test was ended when the 
subject demanded cessation of the treadmill due to exhaus-
tion, or if the HR achieved was more than 90% of estimated 
maximal HR (220 – age), or if the RPE was more than 17. 
The predictive VO
2
max value was calculated using the ACSM 
walking equation as outlined below.25
VO
2
 = 0.1 (speed) + 1.8 (speed) (fractional grade) + 3.5 (4)
leg strength test (dynamometry assessment)
The subjects performed leg strength test using the back and 
leg dynamometer. The subjects were asked to stand on the 
platform with their trunk erected and the knees flexed to an 
angle of 130°–140°. The subjects then held the hand bar using 
a pronated grip, positioning it across their thighs by adjusting 
the length of the chain after which they slowly and gradually 
were asked to exert as much force as possible while extending 
their knees without using their back so that the maximum 
indicator needle remained at the peak force achieved. To 
ensure reproducibility and accuracy, two or three trials with 
a 1-minute rest interval were conducted.25
statistical analyses
Data are presented as mean ± standard deviation. Data 
were analyzed with a commercially available statistical 
software program (SPSS version 17.0). The intergroup and 
intragroup comparisons were assessed using a repeated 
measure of analysis of variance and post hoc Bonferroni 
where appropriate. Indicators for group (CG vs TTG), time 
(in weeks), and an interaction term (group × time) were 
assessed. Values of P,0.05 are considered as statistically 
significant.
Results
Baseline characteristics
There were no significant differences among the four param-
eters (body composition, physical performance, cardiovas-
cular factors, and metabolic factors) at baseline between 
the two groups (CG vs TTG; for all, P.0.05) (Table 2). In 
TTG, four subjects were excluded from the analyses due to 
their inability to complete the training program; four sub-
jects withdrew from the study (one for a minor sole injury 
and three for personal reasons). In CG, four patients were 
excluded from the analyses due to their refusal to perform 
follow-up tests for personal reasons.
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Table 2 Parameters related to the metabolic syndrome before, in the middle of, and after the experimental period
Parameters Control group Test training group
Day 1 (baseline) Week 8 Week 16 Day 1 (baseline) Week 8 Week 16
Body composition
 Weight (kg) 97.18±13.10 97.61±13.10 97.73±13.10 99.30±14.80 97.47±15.50* 96.09±15.10*,†
 Body mass index (kg/m2) 33.85±3.70 34.01±3.70 34.05±3.70 34.70±3.60 34.04±3.90* 33.56±3.80*,†
 Waist circumference (cm) 110.04±6.50 110.09±6.60 110.18±6.50 112.59±9.40 110.95±9.50* 109.15±8.80*,†
 Fat (%) 32.11±5.50 32.48±5.90 32.48±5.80 33.24±4.30 31.45±5.00 30.10±4.90*,†
Physical function
 VO2max (ml/kg/min) 23.35±2.50 23.54±2.70 23.74±2.80 25.02±3.70 29.80±5.12* 29.91±5.10†,‡
 leg strength (kg) 92.77±30.20 93.60±29.30 94.14±29.10 96.61±24.60 106.66±21.56* 118.87±24*,†
cardiovascular factors
 systolic BP (mmhg) 141.36±17.20 141.45±16.50 142.09±16.90 138.81±13.90 130.09±15.20* 126.09±18.70†
 Diastolic BP (mmhg) 89.54±7.40 90.36±7.10 89.72±7.60 91.45±7.20 85.45±7.50* 79.54±8.70*,†,‡
 Mean arterial BP (mmhg) 106.81±9.80 107.39±9.30 106.87±9.60 107.11±8.10 100.33±90* 95.05±11.70*,†
 Maximal heart rate (bpm) 160.09±11.10 160.9±11 161±11.30 166.54±9.30 167.18±9.40 167.09±9.70
Metabolic factors
 Fasting plasma insulin (µIU/ml) 15.19±5.70 15.05±5.60 15.05±5.60 15.89±7.50 11.36±4.70* 10.65±4.50†
 Fasting plasma glucose (mg/dl) 119.54±19.30 119.63±19.40 119.36±19.20 117.72±18.50 108.81±15.50* 106±10.70†
 Insulin resistance (hOMa-Ir) 4.41±1.70 4.38±1.70 4.4±1.70 4.5±20 3.05±1.40* 2.8±1.20†
 Insulin sensitivity (QUIcKI) 0.30±0.01 0.30±0.01 0.30±0.01 0.30±0.02 0.32±0.02* 0.32±0.02†,‡
 hDl (mg/dl) 34.72±5.90 34.81±5.90 34.72±6.00 34.18±5.20 34.27±5.20 35.36±5.30
 Triglycerides (mg/dl) 193.45±53.80 193.54±53.90 193.81±50.60 190.54±41.3 162.36±41.90* 147.09±37.80†
Notes: Data are mean ± standard error. *Significantly different within each group: baseline (day 1) vs week 8 or week 8 vs week 16 (P,0.05); †significantly different within 
each group: baseline (day 1) vs week 16 (P,0.05); ‡significantly different between training group and control group (P,0.05).
Abbreviations: BP, blood pressure; hOMa-Ir, homeostasis assessment model of insulin resistance; QUIcKI, quantitative insulin sensitivity check index; hDl, high-density 
lipoprotein.
Body composition
In TTG, the combined training program resulted in sig-
nificant reductions in total body weight (up to 3.2%), BMI 
(up to 1.1 kg/m2), and waist circumference (up to 3.4 cm) 
at the end of first 8 weeks, second 8 weeks, and over the 
16 weeks after adjusting for the baseline values (all P,0.05). 
 Compared with baseline, there were significant reductions 
in subcutaneous fat mass at week 16 (up to 3.1%, P,0.05) 
but not at week 8. Interestingly, in CG, there were no sig-
nificant changes observed in any of these parameters (for 
all, P.0.05) (Table 2).
Physical performance
In TTG, there were significant improvements in maximal 
oxygen consumption (VO
2
max) by 19.1% and 19.5% at 
weeks 8 and 16, respectively (for both, P,0.05), compared 
with their baseline level. However, there were no differences 
between improvements seen at week 8 and week 16 (P.0.05) 
(Table 2). Compared with baseline levels, the maximum leg 
strength was significantly improved by 10.04 kg and 22.25 kg 
at week 8 and week 16 (P,0.05), respectively. Interestingly, 
the improvement in maximum leg strength was continuous 
with significant difference between week 8 and week 16 
(12.2 kg improvement vs week 8 value, P,0.05) (Table 2). 
There was no significant difference in any physical perfor-
mance parameters in CG compared with their baseline levels 
(Table 2).
Blood pressure
In TTG, the combined training program significantly reduced 
systolic and diastolic BP at week 16 by 12.7 mmHg and 
11.9 mmHg (for both, P,0.05), respectively (Table 2). 
 Importantly, improvement in BP was evident at week 8 
 (systolic: 8 mmHg and diastolic: 6 mmHg, P,0.05) (Table 2). 
The reduction in diastolic but not systolic BP during the 
 second 8 weeks was significant compared with the first 
8 weeks (week 16: 79.5 mmHg vs week 8: 85.5 mmHg, 
P,0.05) (Table 2). Once again, no significant changes were 
observed in any of these indices within the CG (P.0.05) 
(Table 2).
Maximal heart rate
There were no changes in MHR in either TTGs or CGs 
 compared with their baseline characteristics (Table 2).
Glycemic and lipid profiles
In TTGs, there were significant (for all, P,0.05) reduc-
tions in plasma glucose (-10%: 11.27 mg/dL), insulin 
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(-33%: 5.24 µIU/mL), and triglycerides (-23%: 43 mg/dL) 
at the end of the study (week 16) compared with their baseline 
values. Moreover, HOMA-IR values were also reduced in 
TTG (-1.7 U) indicating improvement in insulin resistance 
(Table 2). Indeed, insulin sensitivity analysis confirmed a 
significant increase (7%, P,0.05) in TTG at week 8. There 
was also a numerical increase in plasma HDL concentrations 
(3.4%: 2 mg/dL) at week 8 in TTGs, but it did not reach sta-
tistical significance (P.0.05) level. Interestingly, no further 
reductions in any of the above biochemical parameters were 
seen during the second 8 weeks in TTG. In CG, there were 
no significant changes observed in any of above indices at 
any stage of the study period (Table 2).
changes in medications
At the end of the study period, anti-diabetes medications 
(sulfonylureas: glibenclamide) but not metformin were 
reduced by 17.2% (by dosage) in TTG. There were no other 
changes in medications (lipid-lowering, antihypertensive 
agents) in either TTGs or CGs. At the end of the experimental 
period (week 16) in TTG, 54% (six out of eleven patients) 
could no longer be considered as patients with the metabolic 
syndrome (Table 3). Importantly, these observations were 
made in the presumed absence of dietary changes during the 
training period (data not shown).
Discussion
With increasing chronological age, there is a tendency to 
accumulate excess weight, often with consequentially marked 
increase in adiposity. Nearly four decades ago, an eloquent 
study reported that body fat in adults may double between 
the ages of 20 years and 60 years, resulting in an increased 
risk for the development of type 2 diabetes mellitus (T2DM) 
and cardiovascular disease.26 Obesity per se is directly asso-
ciated with poor cardiovascular outcomes.27,28 Conversely, 
reductions in adiposity (physiologically, pharmacologically, 
or surgically) have been shown to improve and in some 
cases completely reverse T2DM and improve cardiovascular 
function.29–31
In this study, 16-week lifestyle intervention (combined 
continuous and interval aerobic training program) sig-
nificantly improved risk factor markers for T2DM (fasting 
plasma glucose and insulin levels, HOMA-IR, and QUICKI) 
and cardiovascular risk factors (adiposity, BP, and lipid pro-
file) indicating a clear positive impact of our intervention 
program in these subjects. Moreover, subjects in TTG patients 
had significantly improved muscular strength, a finding that 
can guide us for effective management of fatigue in patients 
with T2DM. In patients with T2DM, there is a persistent 
muscular weakness in particular in slow twitch muscles 
(arms and legs).32 The exact mechanism(s) of this phenom-
enon is not fully understood yet. However, it is possible that 
a) persistently high plasma glucose (hyperglycemia) may 
exert toxic effect (glucotoxicity) on muscle fibers, or b) the 
diabetes-induced neuropathy may impede optimal muscular 
function. Alternatively, diabetes-induced endothelial dam-
age may limit oxygen delivery to muscular tissue in T2DM 
patients, resulting in their decreased performance. Indeed, 
reductions observed in circulating plasma glucose and insu-
lin as well as increase in VO
2
max in TTG provide plausible 
arguments for above hypotheses. Other possible explanations 
may include interference of high level of intramuscular 
triacylglycerides,33 or alterations in insulin responsiveness 
of muscle fibers.34 However, further mechanistic studies are 
required to elucidate the exact mechanism(s) involved in 
muscular weakness in T2DM.
The most remarkable finding in our study is that improve-
ments observed by our combined continuous and interval 
aerobic training program were not transient. The program 
had significant positive effects at week 8 followed by further 
improvements at week 16, with the exception of plasma glu-
cose and insulin levels. This in turn suggests that biochemical 
Table 3 Number of patients with metabolic syndrome according to ATP III definition at day 1 (baseline), week 8, and week 16 of the 
study period
Number of patients and factors Control group Test training group
Day 1 (baseline) Week 8 Week 16 Day 1 (baseline) Week 8 Week 16
average number of metabolic syndrome factors 3.9 3.81 3.81 4 3.36 2.72
Patients with metabolic syndrome, n* 11/11 10/11 10/11 11/11 8/11 5/11
Waist circumference, n* 11/11 10/11 11/11 9/11 8/11 8/11
Fasting glucose, n* 7/11 7/11 6/11 7/11 4/11 4/11
high-density lipoprotein, n* 9/11 9/11 9/11 10/11 10/11 9/11
Triglycerides, n* 8/11 8/11 8/11 10/11 8/11 6/11
Blood pressure, n* 8/11 8/11 8/11 8/11 7/11 3/11
Note: *The first number is the number of patients of whom data was obtained, and the second number is the total number of patients in that study group. 
Abbreviation: aTP, adult Treatment Panel.
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and anthropometric improvement (reduction in % fat, total 
body weight, waist circumference, BMI, and increased mus-
cular strength) is a continuous flow that could be achieved in 
proportion to the length and volume of the training program, 
underlining the need for continuous care program for such 
patients. In other words, there is a clear evidence indicating 
susceptibility of the patients’ physiological being to adapt to 
lifestyle (exercise) changes, further underscoring the impor-
tance of the diet and exercise regimen in managing sequelaes 
of obesity and T2DM. In practice, the continuum of care does 
not exist which may explain our collective failure in manag-
ing obesity and T2DM-related health problems.
As mentioned above, there were no significant changes 
in plasma glucose and insulin levels between week 8 and 
week 16. The main reason for this apparent stagnation of the 
metabolic improvement is that after the first 8 weeks, the fast-
ing plasma glucose and insulin levels in TTG were returned 
to near-normal levels (fasting plasma glucose: 108 mg/dL and 
insulin: 11 µIU/mL), which suggests that maximum effect has 
already been reached by 8 weeks of our exercise program. 
This finding can have major implications in management of 
patients with prediabetes and T2DM.
The fat tissue provides the required fuel for exercising 
muscle during an aerobic training period. The triacylglycer-
ides are first hydrolyzed, and the resultant fatty acids are then 
transported by blood flow and delivered to the mitochondria 
of working muscle where they are oxidized. Although the 
lipolytic rate remains relatively high with increasing exer-
cise intensity, the release of fatty acids into the circulation 
declines suggesting that increasing exercise intensity inhibits 
fat oxidation by inhibiting the carnitinepalmitoyltransferase 
1A and carnitine-mediated transport of fatty acids into mito-
chondria.35 In fact, it appears that that maximal fat oxidation 
occurs at around 42%±6% VO
2
max (62%±5% MHR) with 
average fat oxidation rate of 0.45±0.07 g/min.36 Thus, an 
exercise training program at an intensity that elicits maximal 
rates of fat oxidation (ie, Fatmax)37 may be a useful armament 
in weight loss programs and health-related exercise programs. 
Interval training markedly increases (2.5- to 15-fold) insulin 
receptor phosphorylation (and thus activation) in muscle and 
fat tissue.8 In our study, combined continuous and interval 
training program improved metabolic syndrome markers 
(hyperglycemia, hyperinsulinemia, insulin sensitivity, and 
insulin resistance indexes) which may have contributed 
to increased fat utilization and metabolism leading to decrease 
in % fat levels in TTG. Taking together previous reports, it 
is plausible that there was approximately 20% increase in 
VO
2
max in TTG pointing to increased rate of fat oxidation, 
a mechanism which may also have contributed to reduction 
in adiposity. Therefore, we propose that the “continuous 
training” could be considered as part of a Fatmax training 
regimen. However, our finding is in contrast to two previous 
reports where no significant effect of endurance exercise on 
body composition indices in metabolic syndrome patients 
was seen.38,39 These contrasting results may be due to the use 
of different training equipment and/or patient selection. For 
instance, both the previous studies38,39 conducted the bulk of 
their aerobic training on the “cyclo-ergometer” equipment, 
whereas in this study, the “treadmill” was used during the 
entire program accounting for reduction in % fat, since the 
rate of fat oxidation is higher during running than activity 
on cyclo-ergometer.40
Metabolic syndrome patients have lower physical fit-
ness levels than healthy individuals.32,41 There appears to be 
a strong link between physical function and mortality such 
that improving physical function improves overall mortality 
rate.42,43 In this study, there was a steady increase (baseline to 
week 8 and week 8 to week 16) in aerobic power of the lower 
limb in TTG implying the importance of increased intensity 
and duration of the overload to achieve optimal leg strength. 
This steady increase in the maximum leg strength signifies 
non-saturation index (desensitization) to the volume and 
intensity of the exercises prescribed in our program. Further-
more, progressive improvement in leg strength seen in our 
study may be at least in part due to reduction in intramuscular 
triacylglyceride33 and increase in capillary density, muscle 
mass, citrate synthetase activity, cellular oxidative capacity, 
and maximal stroke volume that limits VO
2
max.8,44
The obese and diabetic patients almost always present 
with hypertension. The presence of the metabolic syndrome 
amplifies hypertension-related end-organ damages (eg, car-
diac and renal) over and above the potential contribution of 
each single component of this syndrome.45 These patients 
are often on a number of pharmacological agents to main-
tain optimal BP. However, despite the use of polypharmacy, 
optimal target BP is rarely achieved.45 In this study, there was 
a progressive BP reduction in TTG at week 8 and week 16 
compared to their respective baseline. Although we did not 
directly measure changes in arterial elasticity or the level of 
nitric oxide production, it is possible that aerobic exercise 
increased shear stress (stimulating production of nitric oxide) 
in the artery, leading to improved arterial endothelial func-
tion and subsequent decrease in arterial BP. Furthermore, 
reduction in plasma insulin level seen at week 8 and week 
16 may have removed vasoconstrictor pathway of insulin (via 
endothelin response) leading to lower arterial BP.45
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In summary, there is a fast and progressive increase 
in the incidence and prevalence of obesity and metabolic 
abnormalities (metabolic syndrome). Obese patients with 
metabolic syndrome are at increased risk of developing 
diabetes and cardiovascular disease which would result in 
premature morbidity and mortality. The lifestyle change 
remains to be the cornerstone of therapy algorithm. 
However, the most significant challenge in the manage-
ment of these conditions remains to be the buy-in from the 
patients for adequate lifestyle changes. We have shown in 
this study that a relatively modest but persistent lifestyle 
change (a programmed exercise regime) would result in 
improvements in body composition, physical performance, 
cardiovascular factors, and metabolic factors to an extent 
of disease reversal in some patients. Therefore, the find-
ings from our study indicate that a “combined continuous 
and interval aerobic training” could offer an optimal non-
pharmacological tool in management of risk factors in 
patients with metabolic syndrome.
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